Inhibition of the poly[ADP-ribose] polymerase 1 (PARP1), which is now an established therapy in recurrent ovarian and metastatic BRCA-mutated breast cancer, also induces CXCR3 chemokines via the STING (stimulator of interferon genes) pathway in tumor cells, whereby the subsequent attraction of immune cells is critical for their function [94–99]. This evidence concerns the gene PARP1 and neoplasm.